Thursday, November 12, 2026

USD/EUR Went Down By Over 1% In The Last 21 Sessions

USD/EUR Went Down By Over 1% In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.59% for the last 21 sessions. At 04:12 EST on Monday, 26 June, USD/EUR (USDEUR) is $0.92.

USD/EUR's yearly highs and lows, it's 1.819% up from its 52-week low and 12.44% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a positive 0.07%, a negative 0.11%, and a positive 0.36%, respectively.

USD/EUR's highest amplitude of average volatility was 0.40% (last week), 0.35% (last month), and 0.36% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be oversold (<=20).

News about

  • Eur/usd: weekly forecast 25th June - 1st July - 25 June 2023. According to DailyForex on Sunday, 25 June, "Traders looking for upside price action in the EUR/USD may be proven correct, but it may take strong emotional fortitude to bet on upwards price action early this week. ", "Forex traders of the EUR/USD were 'treated' to a couple of days of fireworks from the currency pair. "
  • Eur/usd pares recent losses around 1.0900 with eyes on eu/us inflation, ECB forum. According to FXStreet on Sunday, 25 June, "On the other hand, Ning Jizhe, deputy head of the economic committee of the Chinese People's Political Consultative Conference (CPPCC) and a former vice head of the National Development and Reform Commission (NDRC) flagged concerns about sooner stimulus from China and allowed the EUR/USD to rebound, due to its business ties with Beijing. ", "Failure to provide a daily closing below the 50-DMA, around 1.0870 by the press time, joins the nearly oversold RSI (14) line to trigger the EUR/USD pair's bounce towards the 10-DMA hurdle of 1.0920."
  • Eur/usd trades with a mild positive bias just above 1.0900, lacks follow-through. According to FXStreet on Monday, 26 June, "Furthermore, HCOB's flash Composite Eurozone PMI sank to a five-month low, which adds to worries about economic headwinds stemming from rising borrowing costs and contributes to keeping a lid on the EUR/USD pair.", "The EUR/USD pair kicks off the new week on a positive note and moves further away from over a one-week high - levels just below mid-1.0800s touched on Friday. "
  • Eur/usd price analysis: retreats from 200-hma with eyes on ecb’s lagarde. According to FXStreet on Monday, 26 June, "On the contrary, the mid-June swing high around 1.0860 precedes the 50% Fibonacci retracement level of June 06-22 upside, near 1.0840, to limit the short-term downside of the EUR/USD pair.", "It's worth noting that the cautious sentiment and the 200-HMA, around 1.0915 at the latest, aren't the only challenges for the EUR/USD bulls as a convergence of the 50-HMA and the previous support line from June 06, close to .0930 at the latest, also prod the Euro pair buyers."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com